Tag:
RegeneRx
Latest Headlines
Latest Headlines
RegeneRx sets sights on dry-eye treatment
RegeneRx, a Rockville, MD-based biopharmaceutical company, has decided to put most of its resources for the near term into its dry eye treatment, RGN-259, the company announced in a news release.
Regulators slap clinical hold on RegeneRx heart drug study
RegeneRx has been forced to slam the brakes on a mid-stage study of RGN-352, its injectable formulation of Thymosin beta 4 for acute myocardial infarction. According to the company, regulators said
Formatech program donates fill/finish for RegeneRx's MS candidate
Formatech will donate aseptic fill and finish services for one lot of a RegeneRx Biopharmaceuticals' drug candidate to treat cardiovascular and central nervous system diseases. The donation is part
RegeneRx, PharmEng cut salaries
Two companies have announced salary cuts and other cost-containment measures today. First, we have RegeneRx Biopharmaceuticals. The company said that its largest stockholder--Sigma-Tau Group--has
RegeneRx refocuses development program
RegeneRx said that based on encouraging "compassionate use" data showing RGN-259's potential healing effects in patients with non-healing corneal ulcers, the company will close its current Phase II
